News
Wed, 31 Jan 2024 05:54:00 -0500
Wed, 31 Jan 2024 05:54:00 -0500
Financial report for the period 1 January 2023 to 31 December 2023
|
PROFIT AND LOSS |
2023 |
2022 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
33,711 |
25,011 |
31% |
36% |
|
Operating profit |
14,888 |
10,573 |
37% |
44% |
|
|
|
|
|
|
|
Net profit |
12,146 |
7,848 |
51% |
N/A |
|
Diluted earnings per share (in USD) |
2.70 |
1.73 |
52% |
N/A |
|
* CER: Constant exchange rates (average 2022). ** For convenience Danish kroner has been translated to USD in the release, using the average exchange rate of USD 1.0 = DKK 6.88970 and the period-end exchange rate of USD 1.0 = DKK 6.74471. |
||||
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments. We continue to make progress on our strategic aspirations. Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity."
On 31 January 2024 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
|
Financial calendar |
|
|
|
7 March 2024 |
Capital Markets Day 2024 in Copenhagen |
|
|
21 March 2024 |
Annual General Meeting |
|
|
2 May 2024 |
Financial results for the first three months of 2024 |
|
|
7 August 2024 |
Financial results for the first half of 2024 |
|
|
6 November 2024 |
Financial results for the first nine months of 2024 |
|
Novo Nordisk’s Annual Report 2023 is available at https://www.novonordisk.com/investors/annual-report.html